The Effect of Using Candesarsan and Amlodipine for Hypertensive Patients with Dyslipidemia in Japan

The Effect of Using Candesarsan and Amlodipine for Hypertensive Patients with Dyslipidemia in Japan - EARTH-trial

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005817

Enrollment

Registered

2011-06-22

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Dyslipidemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hypertensive patients Systolic blood pressure>140 mmHg or Diastolic blood pressre.90 mmHg or Already taking antihypertensive drugs 2. High levels of LDL cholesterol patients LDL-C>140 mg/dl or LDL-C>100 mg/dl and need to take statints by attending physician or Already taking statins

Exclusion criteria

Exclusion criteria: 1.Malignancy 2.Contraindication to take candesartan, amlodipine and pitabastatin. 3.Familial hypercholesterolemia 4.Acute coronary syndrome 5.Already enrollment other clinical trials. 6.Mismatched patients

Design outcomes

Primary

Measure	Time frame
The blood pressure-lowering effect was not significant difference among candesartan and amlodipine groups. Moreover, candesartan group was not worsening insulin resistance and the effect of lipid metabolism in hypertensive patients with dyslipidemia.	—

Countries

Japan

Outcome results